Imipramine increases fatty liver scores and is linked to adipogenesis in the liver, including FABP4 and SREBP1 mRNA levels, in addition to adiponectin, FASN, and PNPLA3 activation. This evidence concerns the gene FABP4 and fatty liver disease.